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Abstract
Central giant cell lesions of the jaws are not uncommon. While the majority of these represent single, sporadic 
lesions, histologically identical lesions are seen in association with a number of other bone lesions, as well as in 
certain syndromes. This manuscript offers a brief update on recent developments in this area that provide new 
insight into the pathogenesis and nature of Central Giant Cell Lesions of the Jaws.
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Introduction
Central giant cell containing lesions of the jaws repre-
sent a heterogeneous group of relatively uncommon 
lesions, the protypical member of this group being the 
Central Giant Cell Lesion (CGCL).
These jaw lesions were previously classified under the 
rubric “giant cell variant of osteitis fibrosa”, or in the 
case of aggressive variants, characterized by one or 
more of extensive destruction, recurrence, loose teeth, 
cortical perforation, root resorption and/or, paresthesia, 
were regarded as a gnathic variant of the Giant Cell Tu-
mor (GCT) of long bones. In 1953, Jaffe (1), introduced 
the term “giant cell reparative granuloma”, to convey 
both the presumed non-neoplastic nature of this process 
and to distinguish it from the GCT of extragnathic ske-
leton.
Among the many unanswered questions with respect to 
CGCLs of the jaws, arguably two of the most widely 
contemplated are: 1) defining the relationship between 
the spectrum of conditions that present with histologi-
cally indistinguishable lesions, and 2) the relationship 
between CGCLs of the jaw and extragnathic GCT.
Pathogenesis of CGCL-like lesions in the spec-
trum of conditions presenting with histologica-
lly indistinguishable lesions
Lesions histologically indistinguishable from sporadic 
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CGCLs of the jaws are seen in peripheral gnathic lo-
cations (peripheral giant cell granuloma (2,3), and in 
association with hyperparathyroidism (“brown tumor” 
of hyperparathyroidism). CGCL-like areas are also de-
scribed in a greater than expected prevalence in asso-
ciation with other centrally-occurring jaw lesions, prin-
cipally central odontogenic fibroma (4,5).
CGCL-like lesions of the jaws are the hallmark of 
cherubism, an autosomal dominantly inherited condi-
tion caused by mutations in the Sh3bp2 gene (6). Sh3-
bp2 codes for SH3-domain binding protein 2 (3BP2), 
a cytoplasmic adaptor protein that positively regulates 
transcriptional activity. Specifically, 3BP2 turnover is 
regulated by tankyrase-mediated poly(ADP-ribosyl)
ation, which targets it to the ubiquitin-proteasome com-
plex for degradation. In cherubism, mutated 3BP2 is 
uncoupled from protein destruction, resulting in 3BP2 
stabilization and increased activation of SRC, SYK, and 
VAV signaling pathways, driving the osteoclast differ-
entiation that is characteristic of cherubism. However, 
studies have, for the most part, failed to identify cheru-
bism-associated Sh3bp2 mutations in sporadic CGCL 
cases (7,8).
A greater than anticipated prevalence of CGCL-like 
jaw lesions has also been observed in patients present-
ing with a number of syndromes. While not a univer-
sal occurrence,  CGCL-like lesions of the jaws, often 
multiple in presentation (a rare occurrence in sporadic 
cases of CGCL, the vast majority of which present as 
a single lesion) have been reported in patients with 
Noonan syndrome (9,10); caused by multiple gene de-
fects including PTPN11, KRAS, NRAS, SOS1, RAF1, 
BRAF, MAP2K1, SHOC2, CBL), neurofibromatosis 
type I (11,12); caused by NF1 mutations), cardiofacio-
cutaneous syndrome; caused by multiple gene defects 
including BRAF, MAP2K1, MAP2K2, and KRAS), and 
Noonan syndrome with multiple lentigines (also known 
as LEOPARD syndrome; associated with gene defects 
including PTPN11, RAF1, and BRAF). Arguing against 
a direct genotype-phenotype association is the find-
ing that a diverse group of syndrome-associated gene 
mutations have been identified in syndromic patients 
presenting with CGCL-like lesions of the jaws; includ-
ing PTPN11, SOS1, BRAF, and MEK1 in  Noonan Syn-
drome (13), BRAF and MEK1 in cardiofacio-cutaneous 
syndrome (13), and PTPN11 in Noonan syndrome with 
multiple lentigines (14). These syndromes have in com-
mon that they are characterized by overlapping facial 
and skeletal features and are caused by mutations at dif-
ferent points along the Ras/MAPK (mitogen-activated 
protein kinase) pathway, resulting in dysregulation of 
Ras/MAPK signaling. As a result, these different con-
ditions are now grouped together under the category of 
“RAS/MAPK syndromes”; or “RASopathies”. While 
the exact pathogenesis linking alteration in the Ras/
MAPK signal transduction pathway to the development 
of CGCL-like lesions in only a small subset of affected 
individuals remains to be determined, the RAS/MAPK 
pathway appears to be important in bone homeostasis.
Affected skeletal changes common to the RASopathies 
include include short stature, osteoporosis, chest wall 
deformities, scoliosis, and generalized increased bone 
resorption (15). In aggregate then, these findings sug-
gest that CGCL-associated lesions of the jaws represent 
a diverse group of lesions in which osteoclastic over-
activity is the hallmark feature which, in conjunction 
with as of yet unidentified precipitating factors; possi-
bly to include trauma and vascular compromise, in pre-
disposes to osteoclastic fusion a susceptible individual. 
The question remains as to what additional factors in 
the bone microenvironment are involved in tipping the 
balance from physiologically altered but otherwise his-
tologically normal appearing bone to outright CGCL 
development.
Relationship between CGCLs of the jaw and ex-
tragnathic GCT
Discussions as to whether all aggressive CGCL lesions 
of the jaw are within the spectrum of CGCL (16) or 
whether subsets represent a gnathic variant of the GCT 
of the long bone persist (17,18).
Behjati and colleagues (19) identified somatic mutations 
in the H3F3A gene, one of two genes coding for histone 
H3.3, in their patients with extragnathic GCTs. These 
mutations, reportedly restricted to the stromal cell po-
pulation, led to amino acid substitutions of glycine 34 to 
tryptophan (p.Gly34Trp) or leucine (p.Gly34Leu) in 49 
of 53 giant cell tumors of bone examined. Interestingly, 
the same authors reported p.Lys36Met alterations in 73 
of 77 chondroblastomas; 5 involving the H3F3A gene 
and 68 involving H3F3B, the second gene encoding for 
histone H3.3.
While the mechanism by which these mutations pre-
dispose to GCT of extragnathic sites remains undefi-
ned, insight into the role of similar H3F3A mutations 
(p.Lys27Met, p.Gly34Arg and p.Gly34Val) in the deve-
lopment of glioma suggests a role for epigenetic trans-
criptional activation (20). Lys27Met-mutated gliomas 
are characterized by an almost complete absence of the 
trimethylated lysine residue H3K27me3 in all isoforms 
of histone H3, the main function of which is to repress 
transcriptional activity in chromatin. It follows, therefo-
re, that the resultant loss of Lys27 methylation leads to 
the upregulation of multiple genes.
However, Gomes and colleagues (21) demonstrated that 
sporadic CGCL of the jaws do not share the H3F3A 
p.Gly34Trp or p.Gly34Leu mutations reported in GCT 
of long bones. These findings appear to add to the body 
of evidence that the CGCL of the gnathic bone is dis-
tinct and separate from the extragnathic GCT.
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Interestingly, an additional recent study suggests that 
the relationship between H3F3A mutations and GCT pa-
thogenesis may not be so clear. Kaneko and colleagues 
(22) were unable to identify the same H3F3A mutations 
described by Behjati and colleagues (19) in any of 20 
Asian patients with GCT of the extragnathic skeleton. 
Instead, in majority of their GCT patients, they reported 
specific isocitrate dehydrogenase gene mutations.
Conclusion
While significant progress continues in our quest to un-
derstand this enigmatic group of conditions, much re-
mains to be defined with respect to the pathogenesis of 
CGCLs of gnathic bone.
References
1. Jaffe HL. Giant-cell reparative granuloma, traumatic bone cyst, 
and fibrous (fibro-oseous) dysplasia of the jawbones. Oral Surg Oral 
Med Oral Pathol. 1953;6:159-75. 
2. Parbatani R, Tinsley GF, Danford MH. Primary hyperparathyroid-
ism presenting as a giant-cell epulis. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod. 1998;85:282-4.
3. Lester SR, Cordell KG, Rosebush MS, Palaiologou AA, Maney P. 
Peripheral giant  cell granulomas: a series of 279 cases. Oral Surg 
Oral Med Oral Pathol Oral Radiol. 2014;118:475-82.
4. Allen CM, Hammond HL, Stimson PG. Central odontogenic fibro-
ma, WHO type. A report of three cases with an unusual associated 
giant cell reaction. Oral Surg Oral Med Oral Pathol. 1992;73:62-6.
5. Odell EW, Lombardi T, Barrett AW, Morgan PR, Speight PM. Hy-
brid central giant cell granuloma and central odontogenic fibroma-
like lesions of the jaws. Histopathology. 1997;30:165-71.
6. Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, et 
al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 
cause cherubism. Nat Genet. 2001;28:125-6.
7. Idowu BD, Thomas G, Frow R, Diss TC, Flanagan AM. Mutations 
in SH3BP2, the cherubism gene, were not detected in central or pe-
ripheral giant cell tumours of the jaw. Brit J Oral Maxillofac Surg. 
2008;46:229-30.
8. Teixeira RC, Horz HP, Damante JH, Garlet GP, Santos CF, Noguei-
ra RL, et al. SH3BP2-encoding exons involved in cherubism are not 
associated with central giant cell granuloma. Int J Oral Maxillofac 
Surg. 2011;40:851-5.
9. Cohen MM, Gorlin RJ. Noonan-like/multiple giant cell lesion syn-
drome. Am J Med Gen. 1991;40:159-66.
10. Edwards PC, Fox J, Fantasia JE, Goldberg J, Kelsch RD. Bilateral 
central giant cell granulomas of the mandible in an eight year-old 
girl with Noonan syndrome (Noonan-like/multiple giant cell lesions 
syndrome). Oral Surg Oral Pathol Oral Med Oral Radiol Endodon. 
2005;99:334-40.
11. Kerl H, Schroll K. Multiple giant cell granulomas of the jaws 
associated with Recklinghausen’s neurofibromato-sis. Wien Klin 
Wochenschr. 1971;83:938-41.
12. Edwards PC, Fantasia JE, Saini T, Rosenberg T, Ruggiero S. 
Clinically aggressive central giant cell granulomas in two patients 
with neurofibromatosis 1. Oral Surg Oral Pathol Oral Med Oral Ra-
diol Endodon. 2006;102:765-72.
13. Neumann TE, Allanson J, Kavamura I, Kerr B, Neri G, Noo-
nan J, et al. Multiple giant cell lesions in patients with Noonan syn-
drome and cardio-facio-cutaneous syndrome. Europ J Hum Genet. 
2009;17:420-5.
14. Sarkozy A, Obregon MG, Conti E, Esposito G, Mingarelli R, Pi-
zzuti A, et al. A novel PTPN11 gene mutation bridges Noonan syn-
drome, multiple lentigines/Leopard syndrome and Noonan-like/mul-
tiple giant cell lesion syndrome. Europ J Hum Genet. 2004;12:1069-
72.
15. Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson 
H, Bauer S, et al. Bone resorption in syndromes of the Ras/MAPK 
pathway. Clin Genet. 2011;80:566-73.
16. Amaral FR, Diniz MG, Bernardes VF, Souza PE, Gomez RS, 
Gomes CC. WWOX expression in giant cell lesions of the jaws. Oral 
Surg Oral Med Oral Pathol Oral Radiol. 2013;116:210-3. 
17. Guerrissi JO. Giant cells mandibular lesion: surgical treatment with 
preservation of the dentition. J Craniofac Surg. 2013;24:1394-6.
18. Kulkarni D, Shetty L, Kulkarni M, Mahajan B. Extensive giant 
cell tumour of the mandible: a case report with review. J Maxillofac 
Oral Surg. 2013;12:461-5.
19. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, vanLoo P, 
et al. Distinct H3F3A and H3F3 B driver muta-tions define chondro-
blastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479-82.
20. Lindroth AM, Plass C. Recurrent H3.3 alterations in childhood 
tumors. Nat Genet. 2013;45:1413-4.
21. Gomes CC, Diniz MG, Amaral FR, Guimarães BV, Gomez RS. 
The highly prevalent H3F3A mutation in giant cell tumours of bone 
is not shared by sporadic central giant cell lesion of the jaws. Oral 
Surg Oral Med Oral Pathol Oral Radiol. 2014; 118:583-5.
22. Kaneko MK, Liu X, Oki H, Ogasawaram S, Nakamura T, Saidoh 
N, et al. Isocitrate dehydrogenase mutation is frequently observed in 
giant cell tumor of bone. Cancer Sci. 2014;105:744-8.
Source(s) of support: None
